Home/Pipeline
Program
PreclinicalPhase 1Phase 2Phase 3FiledApproved
Next milestoneCLV-140Small cell lung cancerOncology · Bispecific
Phase 2 data at oncology congress
CLV-226Atopic dermatitisImmunology · Antibody
Phase 2b readout Q4 2026
CLV-318Treatment-resistant depressionNeuroscience · Small molecule
Phase 2 data Q1 2027
CLV-419Heart failure (HFpEF)Cardiometabolic · Antibody
Phase 2 enrollment ongoing
CLV-508Duchenne muscular dystrophyRare Disease · Gene therapy
Pivotal cohort dosing
Pipeline as of September 30, 2026. Programs and data are fictional.